산후 우울증 치료제 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 치료별, 투여 경로별, 유통 채널별, 지역별, 부문별 예측(2024-2030년)

Postpartum Depression Drugs Market Size, Share & Trends Analysis Report By Type, Treatment, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,221,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,602,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,366,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

산후 우울증 치료제 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 산후 우울증 치료제 시장은 2030년까지 15억 9,000만 달러에 달할 것으로 예상되며, 예측 기간 동안 연평균 9.63% 성장할 것으로 예상됩니다.

전 세계 임신 건수의 증가가 시장 성장의 주요 원동력이 되고 있습니다. 많은 여성들이 출산 후 산후 우울증(PPD)을 앓고 있으며, 나중에 주요 우울증으로 발전할 위험이 높습니다. 클리블랜드 클리닉의 추정에 따르면, 산후 우울증은 출산 후 여성 7명 중 1명이 겪는 흔한 질환입니다. 따라서 출산을 경험하고 PDD와 같은 기분 장애를 앓고 있는 여성에 대한 정부 지원이 증가함에 따라 예측 기간 동안 의약품 수요가 증가할 것으로 예상됩니다.

Indian Association of Preventive &Social Medicine에 따르면, 매년 약 3,000만 명의 여성이 임신을 경험하고 2,700만 명의 여성이 출산을 경험하고 있으며, 2022년 7월 인도 정부는 Janani Suraksha Yojana( JSY), Janani Shishu Suraksha Karyakaram(JSSK) 등 임산부를 지원하는 여러 제도를 시작했습니다. 이 프로그램을 통해 정부는 진단, 의약품, 기타 소모품 등 임신과 관련된 치료를 무료로 제공하고 있습니다. 따라서 JSSK 및 JSY와 같은 이니셔티브는 여성이 산후 우울증과 같은 치료를 완료하는 데 도움을 주며 동시에 예측 기간 동안 시장 성장을 촉진합니다.

산후 우울증 치료제의 채택을 촉진하는 또 다른 중요한 요인은 의료 지출 증가로, 이는 인프라를 개선하고 의료 시설에 대한 환자의 접근성을 향상시키는 데 도움이 되고 있습니다. 임신, 출산, 산후 치료에 연간 약 1만 8,865달러를 지출하고 있습니다. 이는 지역별로 큰 편차를 보이며, 지출과 비용은 지역별로 크게 차이가 납니다. 여성의 PPD 치료에 대한 접근성 증가는 향후 몇 년 동안 시장 성장을 촉진할 것으로 예상됩니다.

산후 우울증 치료제 시장 보고서 하이라이트

• 2023년 산후 불안 분야가 가장 큰 시장 점유율을 차지했습니다. 이는 이 질환의 높은 치료율과 선진국 및 신흥국에서 증가하는 유병률에 기인합니다.
• 치료 유형에 따라 호르몬 치료 부문은 예측 기간 동안 가장 빠른 CAGR로 성장할 것으로 예상됩니다. 이는 새로운 호르몬 약물의 개발 및 상용화와 PDD 치료를 위한 소규모 병원 및 시설의 채택 증가에 기인할 수 있습니다.
• 2023년 경구용 의약품은 투여 경로에 따라 시장에서 가장 큰 점유율을 차지했습니다. 이러한 우위는 전 세계적으로 질병의 유병률과 발생률 증가, 제품의 풍부한 가용성, 치료를 위한 새로운 경구용 제네릭 의약품에 대한 수요 증가에 기인합니다.
• 병원 약국 부문은 2023년 유통 채널 기반 시장에서 가장 큰 점유율을 차지했습니다. 이는 병원에서의 치료율, PDD 치료에 있어 환자들이 다른 의료 환경보다 병원을 선호하고, 병원을 방문하는 환자 수가 증가하고 있기 때문입니다.
• 북미는 선진화된 의료 인프라, 질병 유병률 증가, 양호한 규제 환경 등의 요인으로 인해 시장을 장악했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 산후 우울증 치료제 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 견인 요인 분석
  • 시장 성장 억제요인 분석
• 산후 우울증 치료제 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석
  • 파이프라인 분석

제4장 산후 우울증 치료제 시장 : 유형별 추정·동향 분석

• 세계의 산후 우울증 치료제 시장 : 유형 대시보드
• 세계의 산후 우울증 치료제 시장 : 유형 변동 분석
• 산후 우울증 치료제 세계 시장 : 치료, 매출별
• 산후 우울감
• 산후 불안
• 산후 강박장애(OCD)
• 산후 외상후 스트레스 장애(PTSD)
• 산후 공황장애
• 예방

제5장 산후 우울증 치료제 시장 : 치료별 추정·동향 분석

• 세계의 산후 우울증 치료제 시장 : 치료 대시보드
• 세계의 산후 우울증 치료제 시장 : 치료 변동 분석
• 치료별, 매출
• 약물요법
• 호르몬요법
• 기타

제6장 산후 우울증 치료제 시장 : 투여 경로별 추정·동향 분석

• 세계의 산후 우울증 치료제 시장 : 투여 경로 대시보드
• 세계의 산후 우울증 치료제 시장 : 투여 경로 변동 분석
• 투여 경로별, 매출
• 비경구
• 경구
• 기타

제7장 산후 우울증 치료제 시장 : 유통 채널별 추정·동향 분석

• 세계의 산후 우울증 치료제 시장 : 유통 채널 대시보드
• 세계의 산후 우울증 치료제 시장 : 유통 채널 변동 분석
• 유통 채널별, 매출
• 병원 약국
• 소매 약국
• 기타(온라인 약국)

제8장 산후 우울증 치료제 시장 : 치료, 치료 클래스, 투여 경로별 지역 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년 :
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제9장 경쟁 상황

• 기업/경쟁 분류
• 벤더 상황
  • 주요 유통업체 및 채널 파트너 리스트
  • 주요 고객
  • 주요 기업의 시장 점유율 분석, 2023년
  • Sage Therapeutics, Inc.
  • Pfizer Inc.
  • Eli Lilly and Company.
  • GSK plc
  • Merck &Co., Inc.
  • Biogen Inc.
  • Bausch Health Companies Inc.
  • Cipla Inc.
  • Novartis AG.
  • Teva Pharmaceutical Industries Ltd.

ksm

영문 목차

영문목차

Postpartum Depression Drugs Market Growth & Trends:

The global postpartum depression drugs market is anticipated to reach USD 1.59 billion by 2030 and is expected to expand at a CAGR of 9.63% during the forecast period, according to a new report by Grand View Research, Inc. The increasing number of pregnancies worldwide primarily drives market growth. Many women suffer from postpartum depression (PPD) after having a baby and are at high risk of developing major depression later in life. According to the Cleveland Clinic Estimate, postpartum depression is a common condition that affects 1 in 7 women after giving birth to a child. Thus, rising government support for women who had childbirth and are suffering from mood disorders like PDD is expected to boost demand for drugs over the forecast period.

According to the Indian Association of Preventive & Social Medicine, every year, around 30 million women experience pregnancy, and 27 million women have live childbirths. In July 2022, the Government of India launched several schemes to support pregnant women, such as Janani Suraksha Yojana (JSY) and Janani Shishu Suraksha Karyakaram (JSSK). Under these programs, the government offers free of cost treatment related to pregnancy, such as diagnostics, medicines, and other consumables. Thus, initiatives like JSSK and JSY support women in completing treatment such as postpartum depression, simultaneously driving market growth during the forecast period.

Another significant factor driving the adoption of postpartum depression drugs is rising healthcare expenditures, which help to improve infrastructure and improve patient access to healthcare facilities. According to the PETERSON-KFF Health System Tracker report, women spend around USD 18,865 annually on pregnancy, childbirth, and postpartum treatment. There is significant variation. around this, spending and costs vary significantly by region worldwide. The increasing access of women to PPD drug treatment is anticipated to drive market growth in the coming years.

Postpartum Depression Drugs Market Report Highlights:

• The postpartum anxiety segment held the largest share of the market in 2023. This can be attributed to the disease's high treatment rate and growing prevalence in developed and developing countries.
• Based on the treatment type, the hormonal therapy segment is expected to grow at the fastest CAGR during the forecast period.This can be attributed to the development and commercialization of new hormonal drugs and increased adoption by smaller hospitals and facilities for the treatment of PDD.
• In 2023, the oral segment held the largest share of the market based on the route of administration. This dominance can be attributed to the increase in the prevalence and incidence of disease worldwide, the large availability of products, and the rising demand for new generic oral drugs for treatment.
• The hospital pharmacy segment held the largest share of the market based on distribution channels in 2023. Hospital treatment rates, patient preference for hospitals over other healthcare settings for PDD treatment, and the increasing number of patients visiting hospitals.
• North America dominated the market owing to factors such as advanced healthcare infrastructure, rising disease prevalence, and favorable regulatory environment.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Treatment
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment and Treatment outlook
  • 2.2.2. Route of Administration outlook
  • 2.2.3. Distribution Channel and Availability outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Postpartum Depression Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of postpartum depression
    • 3.2.1.2. Advancements in drug development
    • 3.2.1.3. Growing awareness and diagnosis
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of treatment
    • 3.2.2.2. Regulatory challenges for new drug approvals
• 3.3. Postpartum Depression Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pipeline Analysis

Chapter 4. Postpartum Depression Drugs Market: Treatment Estimates & Trend Analysis

• 4.1. Global Postpartum Depression Drugs Market: Type Dashboard
• 4.2. Global Postpartum Depression Drugs Market: Type Movement Analysis
• 4.3. Global Postpartum Depression Drugs Market by Treatment, Revenue
• 4.4. Postpartum Blues
  • 4.4.1. Postpartum blues market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Postpartum Anxiety
  • 4.5.1. Postpartum anxiety market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Postpartum Obsessive-Compulsive Disorder (OCD)
  • 4.6.1. Postpartum obsessive-compulsive disorder (OCD) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Postpartum Post-Traumatic Stress Disorder (PTSD)
  • 4.7.1. Postpartum post-traumatic stress disorder (PTSD) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Postpartum Panic Disorder
  • 4.8.1. Postpartum panic disorder market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Preventive
  • 4.9.1. Postpartum psychosis market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Postpartum Depression Drugs Market: Treatment Estimates & Trend Analysis

• 5.1. Global Postpartum Depression Drugs Market: Treatment Dashboard
• 5.2. Global Postpartum Depression Drugs Market: Treatment Movement Analysis
• 5.3. Global Postpartum Depression Drugs Market Estimates and Forecasts, By Treatment, Revenue (USD Million)
• 5.4. Pharmacotherapy
  • 5.4.1. Pharmacotherapy market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Hormonal Therapy
  • 5.5.1. Hormonal therapy market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Postpartum Depression Drugs Market: Route of Administration Estimates & Trend Analysis

• 6.1. Global Postpartum Depression Drugs Market: Route of Administration Dashboard
• 6.2. Global Postpartum Depression Drugs Market: Route of Administration Movement Analysis
• 6.3. Global Postpartum Depression Drugs Market Estimates and Forecasts, by Route of Administration, Revenue (USD Million)
• 6.4. Parenteral
  • 6.4.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Oral
  • 6.5.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Postpartum Depression Drugs Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Global Postpartum Depression Drugs Market: Distribution Channel Dashboard
• 7.2. Global Postpartum Depression Drugs Market: Distribution Channel Movement Analysis
• 7.3. Global Postpartum Depression Drugs Market Estimates and Forecasts by Distribution Channel, Revenue (USD Million)
• 7.4. Hospital Pharmacy
  • 7.4.1. Hospital pharmacy market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Retail Pharmacy
  • 7.5.1. Retail pharmacy market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Others (Online Pharmacy)
  • 7.6.1. Others (online pharmacy) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Postpartum Depression Drugs Market: Regional Estimates & Trend Analysis by Treatment, Therapeutic Class, and Route of Administration

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Vendor Landscape
  • 9.2.1. List of key distributors and channel partners
  • 9.2.2. Key customers
  • 9.2.3. Key company market share analysis, 2023
  • 9.2.4. Sage Therapeutics, Inc.
    • 9.2.4.1. Company overview
    • 9.2.4.2. Financial performance
    • 9.2.4.3. Product benchmarking
    • 9.2.4.4. Strategic initiatives
  • 9.2.5. Pfizer Inc.
    • 9.2.5.1. Company overview
    • 9.2.5.2. Financial performance
    • 9.2.5.3. Product benchmarking
    • 9.2.5.4. Strategic initiatives
  • 9.2.6. Eli Lilly and Company.
    • 9.2.6.1. Company overview
    • 9.2.6.2. Financial performance
    • 9.2.6.3. Product benchmarking
    • 9.2.6.4. Strategic initiatives
  • 9.2.7. GSK plc
    • 9.2.7.1. Company overview
    • 9.2.7.2. Financial performance
    • 9.2.7.3. Product benchmarking
    • 9.2.7.4. Strategic initiatives
  • 9.2.8. Merck & Co., Inc.
    • 9.2.8.1. Company overview
    • 9.2.8.2. Financial performance
    • 9.2.8.3. Product benchmarking
    • 9.2.8.4. Strategic initiatives
  • 9.2.9. Biogen Inc.
    • 9.2.9.1. Company overview
    • 9.2.9.2. Financial performance
    • 9.2.9.3. Product benchmarking
    • 9.2.9.4. Strategic initiatives
  • 9.2.10. Bausch Health Companies Inc.
    • 9.2.10.1. Company overview
    • 9.2.10.2. Financial performance
    • 9.2.10.3. Product benchmarking
    • 9.2.10.4. Strategic initiatives
  • 9.2.11. Cipla Inc.
    • 9.2.11.1. Company overview
    • 9.2.11.2. Financial performance
    • 9.2.11.3. Product benchmarking
    • 9.2.11.4. Strategic initiatives
  • 9.2.12. Novartis AG.
    • 9.2.12.1. Company overview
    • 9.2.12.2. Financial performance
    • 9.2.12.3. Product benchmarking
    • 9.2.12.4. Strategic initiatives
  • 9.2.13. Teva Pharmaceutical Industries Ltd.
    • 9.2.13.1. Company overview
    • 9.2.13.2. Financial performance
    • 9.2.13.3. Product benchmarking
    • 9.2.13.4. Strategic initiatives

관련자료